Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Practically Speaking: What is the Standard of Care for 1st Line mRCC?

  • Broadcast in Medicine



Follow This Show

If you liked this show, you should follow MedOncNow.

To be added to the distribution list, please email: DDeCastro@southlakeregional.org

In this episode, Dr. Daniel Heng will help us understand when to use which treatment in first line mRCC.  With the new availability for Pembro/Lenvatnib what is the true standard of care now? 

Key Opinion Leader: 

Daniel Heng MD MPH FRCPC
Clinical Professor and Head, Medical Oncology, University of Calgary
Section Chief, Medical Oncology, Tom Baker Cancer Centre
Staff Medical Oncologist, Tom Baker Cancer Centre

Shaqil Kassam MD. MSc. FRCPC
Medical Oncologist
Stronach Regional Cancer Centre, Newmarket, Ontario 

0:00 - Introduction
1:50 – Dr. Daniel Heng Biography
2:40 - SOC in ITT, Intermediate/Poor, Favourable - is there a plateau
16:20 - Checkmate vs. Clear vs. Keynote - Comparisons 
18:20 - Special subgroups - Brain mets, Liver mets, different histologies, CPS/PDL1
22:50 - Progression post adjuvant I/O and 2nd line therapy decisions
26:45 - Pembro/Lenvatanib - Dosing 


Previous episodes: https://www.blogtalkradio.com/medoncnow


Facebook comments

Available when logged-in to Facebook and if Targeting Cookies are enabled